Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ.

Lancet Diabetes Endocrinol. 2019 Sep 5. pii: S2213-8587(19)30256-6. doi: 10.1016/S2213-8587(19)30256-6. [Epub ahead of print]

PMID:
31495651
2.

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.

Koomen JV, Heerspink HJL, Schrieks IC, Schwartz GG, Lincoff AM, Nicholls SJ, Svensson A, Wedel H, Weichert A, Grobbee DE, Stevens J.

Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13862. [Epub ahead of print]

PMID:
31468659
3.

When drug treatments bias genetic studies: Mediation and interaction.

Schmidt AF, Heerspink HJL, Denig P, Finan C, Groenwold RHH.

PLoS One. 2019 Aug 28;14(8):e0221209. doi: 10.1371/journal.pone.0221209. eCollection 2019.

4.

Change in albuminuria as a surrogate endpoint.

Waijer SW, Gansevoort RT, Heerspink HJL.

Curr Opin Nephrol Hypertens. 2019 Aug 22. doi: 10.1097/MNH.0000000000000541. [Epub ahead of print]

PMID:
31449083
5.

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.

Kroonen MYAM, Stevens J, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2019 Aug 15. doi: 10.1111/dom.13849. [Epub ahead of print]

PMID:
31414562
6.

Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.

Dekkers CCJ, Sjöström CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL.

Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13855. [Epub ahead of print]

PMID:
31407856
7.

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists.

van Baar MJB, van der Aart AB, Hoogenberg K, Joles JA, Heerspink HJL, van Raalte DH.

Ther Adv Endocrinol Metab. 2019 Jul 24;10:2042018819865398. doi: 10.1177/2042018819865398. eCollection 2019. Review.

8.

Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.

Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM.

Kidney Int. 2019 May 16. pii: S0085-2538(19)30503-4. doi: 10.1016/j.kint.2019.04.027. [Epub ahead of print]

PMID:
31377056
9.

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.

van Raalte DH, Bjornstad P, Persson F, Powell DR, de Cassia Castro R, Wang PS, Liu M, Heerspink HJL, Cherney D.

Diabetes Care. 2019 Oct;42(10):1921-1929. doi: 10.2337/dc19-0937. Epub 2019 Aug 1.

PMID:
31371432
10.

Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.

Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA.

J Am Soc Nephrol. 2019 Sep;30(9):1756-1769. doi: 10.1681/ASN.2019010009. Epub 2019 Jul 10.

PMID:
31292198
11.

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T.

J Am Soc Nephrol. 2019 Sep;30(9):1735-1745. doi: 10.1681/ASN.2019010007. Epub 2019 Jul 10.

PMID:
31292197
12.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

13.

Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.

Mulder S, Heerspink HJL, Darshi M, Kim JJ, Laverman GD, Sharma K, Pena MJ.

Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13823. [Epub ahead of print]

PMID:
31264758
14.

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10. Erratum in: Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20.

PMID:
31196815
15.

No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives.

Martono DP, Heerspink HJL, Hak E, Denig P, Wilffert B.

Diabetes Obes Metab. 2019 Oct;21(10):2267-2273. doi: 10.1111/dom.13803. Epub 2019 Jun 24.

PMID:
31168905
16.

Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors.

Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR, Faber J, Danser AHJ, Gansevoort RT, Rossing P, Persson F, Heerspink HJL.

J Clin Med. 2019 May 31;8(6). pii: E779. doi: 10.3390/jcm8060779.

17.

Predicting individual treatment response in diabetes.

Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):415-417. doi: 10.1016/S2213-8587(19)30118-4. Epub 2019 Apr 29. No abstract available.

18.

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Idzerda NMA, Stefansson BV, Pena MJ, Sjostrom DC, Wheeler DC, Heerspink HJL.

Nephrol Dial Transplant. 2019 Apr 21. pii: gfz064. doi: 10.1093/ndt/gfz064. [Epub ahead of print]

PMID:
31005993
19.

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

Heerspink HJL, Coresh J, Gansevoort RT, Inker LA.

Lancet Diabetes Endocrinol. 2019 May;7(5):336-337. doi: 10.1016/S2213-8587(19)30080-4. No abstract available.

PMID:
31003622
20.

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G.

Diabetologia. 2019 Jul;62(7):1154-1166. doi: 10.1007/s00125-019-4859-4. Epub 2019 Apr 17.

21.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
22.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13.

PMID:
30992195
23.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

PMID:
30990260
24.

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.

Vinke JSJ, Heerspink HJL, de Borst MH.

Curr Opin Nephrol Hypertens. 2019 Jul;28(4):321-327. doi: 10.1097/MNH.0000000000000505.

25.

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney.

Heerspink HJL.

Nephrol Dial Transplant. 2019 Feb 20. pii: gfz033. doi: 10.1093/ndt/gfz033. [Epub ahead of print] No abstract available.

PMID:
30789206
26.

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Perco P, Pena M, Heerspink HJL, Mayer G; BEAt-DKD Consortium.

Kidney Int Rep. 2018 Dec 18;4(2):212-221. doi: 10.1016/j.ekir.2018.12.001. eCollection 2019 Feb. Review.

27.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

PMID:
30635226
28.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.

PMID:
30635225
29.

New pharmacological strategies for protecting kidney function in type 2 diabetes.

Muskiet MHA, Wheeler DC, Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 May;7(5):397-412. doi: 10.1016/S2213-8587(18)30263-8. Epub 2018 Dec 19. Review. Erratum in: Lancet Diabetes Endocrinol. 2019 Feb 4;:.

PMID:
30579729
30.

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17.

PMID:
30559106
31.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.

Diabetes Care. 2019 Feb;42(2):318-326. doi: 10.2337/dc18-1871. Epub 2018 Dec 6.

PMID:
30523029
32.

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care.

Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, Borrelli S, Garofalo C, Iodice C, De Stefano T, Conte G, Heerspink HJL, De Nicola L.

J Clin Med. 2018 Dec 1;7(12). pii: E499. doi: 10.3390/jcm7120499.

33.

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.

Heerspink HJL, Sjöström CD, Inzucchi SE, Hallow MK, Cain VA, Rossing P, Stefansson BV, Sartipy P.

Diabetes Obes Metab. 2019 Mar;21(3):720-725. doi: 10.1111/dom.13579. Epub 2018 Dec 11.

34.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
35.

ACCORDION: Ensuring That We Hear the Music Clearly.

Wong MG, Heerspink HJL, Perkovic V.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1621-1623. doi: 10.2215/CJN.11370918. Epub 2018 Oct 25. No abstract available.

PMID:
30361334
36.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

PMID:
30314978
37.

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.

Heerspink HJL, List J, Perkovic V.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:14-18. doi: 10.1111/dom.13417. Review.

38.

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.

Mol PGM, Thompson A, Heerspink HJL, Leufkens HGM.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:19-23. doi: 10.1111/dom.13453. Review.

39.

Treating diabetic complications; from large randomized clinical trials to precision medicine.

Heerspink HJL, de Zeeuw D.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:3-5. doi: 10.1111/dom.13418. Review.

40.

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.

Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH.

Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869. doi: 10.1016/S2213-8587(18)30268-7. Epub 2018 Oct 3.

PMID:
30292589
41.

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; apost hoc analysis of the PLANET trials.

Idzerda NMA, Pena MJ, Parving HH, de Zeeuw D, Heerspink HJL.

Nephrol Dial Transplant. 2018 Sep 1. doi: 10.1093/ndt/gfy159. [Epub ahead of print]

PMID:
30184238
42.

Personalized medicine in diabetic kidney disease: a novel approach to improve trial design and patient outcomes.

Idzerda NMA, Pena MJ, Heerspink HJL.

Curr Opin Nephrol Hypertens. 2018 Nov;27(6):426-432. doi: 10.1097/MNH.0000000000000447. Review.

PMID:
30095480
43.

Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics.

Provenzano M, Chiodini P, Minutolo R, Zoccali C, Bellizzi V, Conte G, Locatelli F, Tripepi G, Del Vecchio L, Mallamaci F, Di Micco L, Russo D, Heerspink HJL, De Nicola L; Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology.

Nephrol Dial Transplant. 2018 Jul 23. doi: 10.1093/ndt/gfy217. [Epub ahead of print]

PMID:
30053127
44.

Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.

Hallow KM, Greasley PJ, Helmlinger G, Chu L, Heerspink HJ, Boulton DW.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.

PMID:
30019930
45.

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.

Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5.

46.

Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.

van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wühl E, Schaefer F; ESCAPE Trial Group.

J Am Soc Nephrol. 2018 Aug;29(8):2225-2233. doi: 10.1681/ASN.2018010036. Epub 2018 Jun 21.

47.

How to measure and monitor albuminuria in healthy toddlers?

van den Belt SM, Gracchi V, de Zeeuw D, Heerspink HJL.

PLoS One. 2018 Jun 21;13(6):e0199309. doi: 10.1371/journal.pone.0199309. eCollection 2018.

48.

Immune-unreactive urinary albumin as a predictor of cardiovascular events: the Hortega Study.

Martínez F, Pichler G, Ruiz A, Martín-Escudero JC, Chaves FJ, Gonzalez-Albert V, Tellez-Plaza M, Heerspink HJL, Zeeuw DDE, Redon J.

Nephrol Dial Transplant. 2019 Apr 1;34(4):633-641. doi: 10.1093/ndt/gfy087.

PMID:
29788140
49.

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL.

Nephrol Dial Transplant. 2018 Jul 1;33(7):1280. doi: 10.1093/ndt/gfy135. No abstract available.

50.

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.

Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.

Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. Review.

PMID:
29735306

Supplemental Content

Loading ...
Support Center